BioPartnering North America Attracts Leading Life Science Companies From Across the Globe
SOQUEL, Calif., Feb. 4 /PRNewswire/ -- Technology Vision Group LLC (TVG) is pleased to announce the 2nd Annual BioPartnering North America (BPN) conference will be held on February 8-10, 2004, at the Westin Bayshore Resort and Marina in Vancouver, B.C., Canada. BPN is produced by Technology Vision Group LLC with the support of local hosts - BC Biotech, BIOTECanada and BioAlberta.
Robert Lee Kilpatrick, Partner, Technology Vision Group LLC, is enthusiastic about the international participation that is evidenced in the expanding list of attendees. He comments, "This year's BPN has benefited enormously from the creation of the Global Bioscience Partnership, whose membership includes 28 bioscience associations and agencies from around the world. This partnership was created by Technology Vision Group to bring together stakeholders from emerging bioscience industries in the Asia Pacific region, Europe, North America, and the rest of the world. Looking ahead to 2005, we expect a substantially greater number of delegates to come to Vancouver from outside of Canada."
BPN is the North American version of the distinguished BioPartnering Europe conference held in London each October, which is a cornerstone of the annual conference calendar. Over 650 delegates from 373 various companies have already registered to attend BPN 2004. These numbers include 39 registered pharmaceutical companies and represent a total of 27 countries including Australia, China, Denmark, Finland, Germany, Italy, Japan and the U.K.
"Our inaugural BioPartnering North America conference last year succeeded beyond our wildest dreams in bringing British Columbian biotechnology companies to the attention of a number of delegates from around the biotech world," said Paul Stinson, Executive Director of BC Biotech. "I cannot remember how many times I heard: 'I had no idea that British Columbia had such a dynamic biotech cluster!' From our point of view, BPN 2003 was an enormous success, and we expect that BPN 2004 will be even better."
A hallmark of BPN is the Open House presentations that will feature 56 biopharmaceutical and diagnostics companies that give interactive presentations in specially constructed booths. Presenting companies are available during a 2-hour period for informal discussions with business development executives. BPN also showcases a number of young companies from various parts of the world in the Emerging Company presentations. This year, 16 companies will offer 15-minute podium presentations in the main plenary hall. Each company will then be available for private discussions directly afterwards.
Emerging Company Presenters Ablynx, Gent, Belgium, Founded 2001 Allon Therapeutics, California, USA, Founded 2001 Ambit Biosciences, California, USA, Founded 2001 AmCyte Inc., California, USA, Founded 2001 Biota Inc., California, USA, Founded 2001 Borean Pharma A/S, Aarhus C, Denmark, Founded 2001 Crimson Pharma, New Jersey, USA, Founded 2002 GenPath Pharmaceuticals, Inc., Massachusetts, USA, Founded 2002 Ionix Pharmaceuticals, Cambridge, United Kingdom, Founded 2001 Lorantis Ltd, Cambridge, United Kingdom, Founded 2001 Nuevolution A/S, Copenhagen, Denmark, Founded 2001 PolyMedix Inc., Pennsylvania, USA, Founded 2002 RESprotect GmbH, Saxony, Germany, Founded 2001 Scion Pharmaceuticals, Massachusetts, USA, Founded 2001 Shanghai Genomics, Inc., Shanghai, China, Founded 2001 Sidec Technologies AB, Stockholm, Sweden, Founded 2001Open House Presenters Active Pass Pharmaceuticals, British Columbia, Canada Affymax, Inc., California, USA AnorMED Inc., British Columbia, Canada Antisoma Research Ltd, London, United Kingdom Argenta Discovery Limited, Essex, United Kingdom Astex Technology Ltd., Cambridge, UKatugen AG, Berlin, Germany Avecia Ltd., Delaware, USA AVI BioPharma, Inc., Oregon, USA Avidex, Oxford, United Kingdom Biolex, Inc., North Carolina, USA BioVex Limited, London, United Kingdom BioVisioN AG, Hannover, Germany BTG, London, United Kingdom Cardiome Pharma Corp., British Columbia, Canada Chemokine Therapeutics Corp., British Columbia, Canada Chromos Molecular Systems Inc., British Columbia, Canada Coley Pharmaceutical Group, Inc., Massachusetts, USA Corgentech, California, USA Cyclacel Limited, Dundee, United Kingdom Cytokinetics, Inc., California, USA Diversa Corporation, California, USA Epigenomics AG, Washington, USA Evotec OAI, Oxford, United Kingdom Favrille, Inc., California, USA Forbes Medi-Tech Inc., British Columbia, Canada GenWay Biotech, Inc., California, USA Global Genomics AB, Stockholm, Sweden Global IQ, Alberta, Canada Graffinity Pharmaceuticals AG, Rhode Island, USA Hybridon, Inc., Massachusetts, USA Inex Pharmaceuticals Corporation, British Columbia, Canada Inflazyme Pharmaceuticals, British Columbia, Canada Ingenium Pharmaceuticals AG, Martinsried, Germany Inimex Pharmaceuticals, Inc., British Columbia, Canada InNexus Biotechnology Inc., British Columbia, Canada International Wex Technologies Inc., British Columbia, Canada Ipsat Therapies Ltd, Espoo, Finland JERINI, Berlin, Germany Lucigen Corporation, Wisconsin, USA Maxim Pharmaceuticals, California, USA MedPharm Ltd, London, United Kingdom MorphoSys AG, Martinsried, Germany Morphotek Inc., Pennsylvania, USA NOBEX, North Carolina, USA Novozymes A/S, Bagsvaerd, Denmark Oxford BioMedica, California, USA PanaGin Pharmaceuticals Inc., British Columbia, Canada Plexxikon, California, USA Scottish Biomedical, Glasgow, United Kingdom SemBioSys Genetics Inc., Alberta, Canada Sequenom, California, USA Syngenta-Biopharma, Basel, Switzerland Twinstrand Therapeutics Inc., British Columbia, Canada Vela Pharmaceuticals Inc., New Jersey, USA Produced by: Technology Vision Group LLC Hosted by: BC Biotech, BIOTECanada, and BioAlbertaSponsored by:
Angiotech Pharmaceuticals, Inc., Arnold & Porter, AstraZeneca, BioWa,Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Burrill & Company, Canadian Institutes of Health Research, Cooley Godward LLP, DDB Technology, Farris, Vaughan, Wills & Murphy Barristers & Solicitors, Genome British Columbia, Government of Alberta, Gowling Lafleur Henderson LLP, Industry Canada / Industrie Canada, Leading Edge British Columbia, Merck, PricewaterhouseCoopers LLP, QLT Inc., RBC Financial Group, Simon Fraser University, TAP Pharmaceutical Products Inc., University-Industry Liaison Office - UBC, Vancouver Economic Development Commission, Ventana Clinical Research Corporation, and Western Economic Diversification Canada.
Acumen Journal of Life Sciences, Biotechnology Focus, BioWorld Today, CCNMatthews, Contact Canada®, Department of International Trade, Euro RSCG Life NRP, Global Bioscience Partnership, and U.S. Commercial Service.
Global Bioscience Partnership:
Alsace Development International, APBio, AusBiotech, BayBio, BC Biotech, BIA, BioAlberta, BIOCOM, BioMelbourne Network, BioNova, BIOQuebec, BIO-SA, BIOTECanada, Biotech Consortium India Limited, CIGB, CIMAB S.A., Council of Great Lakes Governors - Australia, Council of Great Lakes Governors Canada Trade Office, DIB, EBE, ERBI, London Development Agency, Metro Atlanta Bioscience Council, Oregon Biosciences Association, and Technology Vision Group LLC.
Technology Vision Group LLC Nancy E. Connelly Phone: (831) 464 7100 email: email@example.com Euro RSCG Life NRP Jeannine Medeiros Phone: (415) 901-3709 email: firstname.lastname@example.org